<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this cooperative study among 13 institutions, 502 patients were treated with antifibrinolytic medication (<z:chebi fb="0" ids="16586">epsilon-aminocaproic acid</z:chebi> or <z:chebi fb="0" ids="48669">tranexamic acid</z:chebi>) within a 14-day period following rupture of an <z:hpo ids='HP_0004944'>intracranial aneurysm</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Mortality at the end of 14 days was 11.6%; proved rebleed rate was 12.7% </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with an internal carotid or anterior <z:hpo ids='HP_0004944'>cerebral aneurysm</z:hpo> had the highest mortality and rebleed rate </plain></SENT>
<SENT sid="3" pm="."><plain>Most rebleeds occurred between the sixth and eleventh days following the initial bleed </plain></SENT>
<SENT sid="4" pm="."><plain>Significantly higher mortality was reported among patients with <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e>, yet rebleed rate was no different among those patients with or without vasospasm </plain></SENT>
<SENT sid="5" pm="."><plain>The same pattern was observed among patients with a mean blood pressure value above and below 110 mm Hg </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that antifibrinolytic therapy provides beneficial treatment to patients with recent <z:hpo ids='HP_0003674'>onset</z:hpo> <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) following rupture of an <z:hpo ids='HP_0004944'>intracranial aneurysm</z:hpo> </plain></SENT>
</text></document>